CAVE CREEK, AZ , Aug. 06, 2024 (GLOBE NEWSWIRE) -- Endexx Corporation (OTCQB:EDXC), a leading provider of innovative plant-based wellness and nutritional products, today announced its financial results for the second quarter of 2024 and provided an update on strategic developments.

Q2 2024 Financial Overview

From the Desk of Brad Listermann, Interim CEO

Dear Shareholders,

As your Interim CEO, I am committed to transparency and proactive communication as we navigate this transitional phase. Our Q2 2024 filing reflects the challenges and opportunities we are currently facing. Below is a detailed overview of our Q2 performance, key developments, and strategic direction.

Bright Spots in Q2

Vaping Industry Growth and HYLA's Potential

The vaping industry continues to evolve rapidly, driven by increasing consumer demand for healthier alternatives to traditional smoking. According to recent market research, the global vaping market is projected to grow at a compound annual growth rate (CAGR) of 23.8% from 2023 to 2030. This growth is fueled by innovation, regulatory changes, and shifting consumer preferences.

HYLA's Positioning:

Strategic Initiatives

Looking Ahead

While we navigate through these changes, the long-term outlook remains positive. Our focus is on leveraging our strengths, optimizing operations, and capitalizing on market opportunities. Your support and trust are invaluable as we continue to build a robust and resilient Endexx.

Thank you for your continued investment and confidence in our company.

Sincerely,

Brad Listermann, Interim CEO, Endexx Corporation

About Endexx Corporation

Endexx Corporation develops and distributes all-natural, plant-derived wellness products and topical skincare products. Its products, ranging from balms, creams, lotions, kinds of butter, masks, scrubs, and oils, are aimed at promoting healthy skin and grooming wellness. The science behind these products involves a decade of clinical research, ensuring functional formulations with ingredients for optimal absorption and skin health support. www.endexx.com

About HYLA

HYLA, a division of Endexx, markets proprietary non-nicotine, guarana, and L-Dopa-based vape products in various flavors. The HYLA device is a first-of-its-kind non-nicotine vape product in the United States, offering up to 4,500 puffs per device. HYLA is currently distributed in 10 countries, with distribution agreements in an additional nine countries. www.tryhyla.com

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

We caution that any forward-looking statements (as such term is defined in the U.S. Private Securities Litigation Reform Act of 1995) contained in this press release or made by us, our management, or our spokespeople involve risks and uncertainties and are subject to change based on various factors, many of which are beyond our control. Accordingly, our future performance and financial results may differ materially from those expressed or implied in any such forward-looking statements. Forward-looking statements include, without limitation, statements regarding our future operating results, the implementation and impact of our strategic plans, and our ability to meet environmental, social, and governance goals. Words such as "estimate," "commit," "target," "goal," "project," "plan," "believe," "seek," "strive," "expect," "anticipate," "intend," "potential," and any similar expressions may identify forward-looking statements. Risks associated with the following factors, among others, could affect our financial performance and cause actual results to differ materially from those expressed or implied in any forward-looking statements.

Except as may be required by law, we assume no obligation and do not intend to make publicly available any update or other revisions to any of the forward-looking statements contained in this press release to reflect circumstances existing after the date of this press release or to reflect the occurrence of future events, even if experience or future events make it clear that any expected results expressed or implied by those forward-looking statements will not be realized. More information on potential factors that could affect our results is included in "Risk Factors" in our Annual Report on Form 10-K filed with the Securities and Exchange Commission.

Contact:

Endexx Corporation

IR@Endexx.com

424-250-0042

www.endexx.com

www.cbdunlimited.com

www.tryhyla.com



Primary Logo